Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12933
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHorowitz, J Den
dc.contributor.authorHenry, C Aen
dc.contributor.authorSyrjanen, M Len
dc.contributor.authorLouis, William Jen
dc.contributor.authorFish, R Den
dc.contributor.authorAntman, E Men
dc.contributor.authorSmith, T Wen
dc.date.accessioned2015-05-16T02:41:47Z
dc.date.available2015-05-16T02:41:47Z
dc.date.issued1988-01-01en
dc.identifier.citationEuropean Heart Journal; 9 Suppl A(): 95-100en
dc.identifier.govdoc3137075en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12933en
dc.description.abstractN-acetylcysteine (NAC) has been shown to potentiate the haemodynamic and antiplatelet effects of nitroglycerine (NTG) in man, and to limit the development of haemodynamic tolerance to NTG. These effects may be mediated. by the formation of S-nitroso-NAC, which induces vasodilation and strongly inhibits platelet aggregation. In a randomized double-blind study in 46 patients with severe unstable angina pectoris unresponsive to standard treatment (including cutaneous nitrates and calcium antagonists in 45 patients) we compared the effects of intravenous (IV) NTG with those of IV NTG combined with IV NAC (5 g 6 hourly). Treatment with NTG/NAC (24 patients) was associated with a similar frequency of episodes of chest pain as treatment with NTG alone (22 patients), but somewhat fewer increments in infusion rate for pain control (10 vs 17; P NS). The NTG/NAC group had a significantly lower incidence of acute myocardial infarction than the NTG/placebo group (3 vs 10 patients; P = 0.013). Symptomatic hypotension occurred frequently in the NTG/NAC group (7 vs 0 patients; P = 0.006). It is concluded that combined administration of NTG and NAC in patients with unstable angina pectoris may augment the clinical efficacy of NTG, largely by reducing the incidence of acute myocardial infarction. However, the high incidence of severe hypotension with NTG/NAC suggests that this regimen should be used with some caution.en
dc.language.isoenen
dc.subject.otherAcetylcysteine.administration & dosage.adverse effects.therapeutic useen
dc.subject.otherAngina Pectoris.drug therapyen
dc.subject.otherAngina, Unstable.blood.drug therapyen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherDrug Therapy, Combinationen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherHypotension.chemically induceden
dc.subject.otherInfusions, Intravenousen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherNitroglycerin.administration & dosage.adverse effectsen
dc.subject.otherRandom Allocationen
dc.titleNitroglycerine/N-acetylcysteine in the management of unstable angina pectoris.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean heart journalen
dc.identifier.affiliationDepartment of Cardiology, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages95-100en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/3137075en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextWith Fulltext-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
3137075.pdf384.79 kBAdobe PDFThumbnail
View/Open
Show simple item record

Download(s)

38
checked on Jan 26, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.